Recombinant PDCD1 (Spartalizumab Biosimilar) antibody

Catalog No. ABIN7581628

The Human Monoclonal anti-PDCD1 (Spartalizumab Biosimilar) antibody has been validated for FACS, BLI, ELISA, Func and SPR. It is suitable to detect PDCD1 (Spartalizumab Biosimilar) in samples from Human.

Quick Overview for Recombinant PDCD1 (Spartalizumab Biosimilar) antibody (ABIN7581628)

Target: PDCD1 (Spartalizumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Human

Clonality: Monoclonal

Conjugate: This PDCD1 (Spartalizumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), Bio-Layer Interferometry (BLI), ELISA, Functional Studies (Func), Surface Plasmon Resonance (SPR)

Product Details anti-PDCD1 (Spartalizumab Biosimilar) Antibody

Expression System: CHO Cells

Purpose: Anti-PDCD1 / PD-1 / CD279 Reference Antibody (spartalizumab)

Characteristics: Anti-PDCD1 / PD-1 / CD279 Reference Antibody (spartalizumab) is expressed from CHO. The heavy chain type is huIgG4SP, and the light chain type is hukappa. It has a predicted MW of 145.56 kDa.

Purity: >95 %

Isotype: IgG4 S228P

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Concentration: 1 mg/mL

Buffer: 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2

Storage: 4 °C,-80 °C

Storage Comment: +4°C,-80°C

Target Details for PDCD1 (Spartalizumab Biosimilar)

Target: PDCD1 (Spartalizumab Biosimilar)

Target Type: Biosimilar

Molecular Weight: 145.56 kDa

UniProt: Q15116